A Kampo preparation, byakkokaninjinto (TJ-34), is commonly used for the improvement of symptoms such as dry mouth, hot flash, and perspiration, and is sometimes coadministered with antimicrobial agents. In general, Kampo preparations contain various herbal medicines and cationic metals such as calcium, magnesium and aluminum, with remarkable differences in each amount. We have previously reported that the Kampo preparations, Hotyu-ekki-to, Rikkunshi-to and Juzen-taiho-to, have no effect on the pharmacokinetics of the quinolone antimicrobial agent levofloxacin in healthy volunteers. 6) To our knowledge, there is no information regarding pharmacokinetic interaction between byakkokaninjinto, which contains a relatively large amount of cationic metals, and antimicrobial agents. However, the therapy with the Kampo preparation is a common practice and is sometimes prescribed without doctors' knowledge of whether or not pharmacokinetic interactions between the Kampo preparation and Western drugs including antimicrobial agents occur.
The aim of the present study is to conduct part of the program for the development of guidelines for the safe use of antimicrobial agents for patients receiving therapy with Kampo preparations. First, we measured the amount of various cationic metals contained in the Kampo preparation, byakkokaninjinto. Second, we evaluated whether concomitant administration with the Kampo preparation would affect the bioavailability and renal excretion of the two selected antimicrobial agents, tetracycline and ciprofloxacin, which are essentially absorbed well from gastrointestinal tract and are primarily excreted into urine as unchanged forms by the kidneys, in young healthy male volunteers.
MATERIALS AND METHODS
Drugs Byakkokaninjinto (TJ-34) was obtained from Tsumura & Co., Tokyo, Japan. The ingredients of the Kampo preparation, which are composed of the dried granules of aqueous extracts from various herbs, are summarized in healthy on the basis of their medical histories, physical examinations, and laboratory tests with blood and urine samples before the study. None of the subjects was given any medications for 7 d prior to and throughout the entire study. None of the subjects was allowed to ingest alcohol 24 h prior to the administration of each drug. They fasted for 16 h from midnight (21:00 p.m.) until 4 h after the administration (13:00 p.m.).
Study Design
The study was of the random crossover fashion, with each subject being under his own control. The study was approved by the Institutional Review Board of Aichi Medical University School of Medicine and written informed consents were obtained prior to the enrollment for the study. Twenty subjects were randomly divided into two groups: ciprofloxacin (200 mg) alone or in combination with one package (3 g) of the Kampo preparation and tetracycline (250 mg) alone or in combination with one package (3 g) of the Kampo preparation, respectively. In the case of coadministration, each antimicrobial agent was administered immediately after ingestion of the Kampo preparation with 180 ml of water at 9:00 a.m. Every subject underwent each of the two studies, with an interval of 7 d as a washout period between each study.
Blood samples (approximately 1 ml) were collected with a vacuum blood collection tube containing EDTA (Venoject II, Terumo, Tokyo, Japan) at time zero (just before the start of administration) and at 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 h for ciprofloxacin and at 1, 2, 3, 4, 6, 8, 12 , and 24 h for tetracycline after each dose. Blood samples were immediately centrifuged to yield plasma. In addition, urine samples were collected 24 h after drug administration. The plasma and 10 ml of each urine sample were stored at Ϫ70°C until analysis.
Drug Analysis Concentrations of tetracycline and ciprofloxacin in plasma and urine were determined by HPLC. The apparatus used for HPLC was a Shimadzu LC-10A system (Kyoto, Japan) equipped with a fluorescence detector (RF-10A XL ; Shimadzu) consisting of an LC-10AT liquid pump and an SIL-10A XL autoinjector. The conditions were as follows: column, a Cosmocil 5C 18 -MSII column (4.6 by 150 nm; Nacalai Tesque, Kyoto, Japan); wave length range, 390 and 335 nm (excitation) and 512 and 450 nm (emission) for tetracycline and ciprofloxacin, respectively; mobile phase, 50 mM sodium acetate buffer (pH 6.5) containing 35 mM calcium chloride and 25 mM disodium ethylenediaminetetraacetate (EDTA) : methanol (70 : 30, [v/v]) for tetracycline and 50 mM citric acid : 1 M ammonium acetate : acetonitrile (87 : 1 : 12, [v/v]) for ciprofloxacin; column temperature, 50°C for tetracycline and 40°C for ciprofloxacin; and flow rate, 1.5 ml/min. For analysis of tetracycline, 100 ml of methanol solution containing 24% of trichloroacetic acid (TCA) and 100 ml of 100 mM sodium acetate buffer (pH 6.5) containing 35 mM calcium chloride and 25 mM EDTA were added to 50 ml of a plasma sample or a urine sample diluted with distilled water (31-fold), and were mixed vigorously and centrifuged at 12000ϫg for 10 min at 4°C. The supernatant (150 ml) obtained was injected to HPLC. For analysis of ciprofloxacin, 100 ml of 24% TCA-methanol solution and 100 ml of the mobile phase containing lomefloxacin (0.25 mg/ml) as an internal standard were added to 50 ml of a plasma sample or a diluted urine sample with distilled water (210-fold) and were mixed vigorously for 1 min. After centrifugation at 12000 g for 10 min at 4°C, 75 ml of the supernatant obtained were injected into HPLC. These assays were linear for the concentrations tested (0.025 to 5 mg/ml and 0.05 to 4 mg/ml for tetracycline and ciprofloxacin, respectively) with a correlation coefficient of 0.999. The withinand between-day coefficients of the variation for these assays were less than 8%. Blank plasma and urine samples did not interfere with the peaks corresponding to each drug and the internal standard.
Analysis of Cationic Metals
The content of calcium, magnesium and aluminum contained in the Kampo preparation was measured by X-Ray fluorescence element analyzer MESA-500 (HORIBA Ltd., Tokyo, Japan). A basic parameter method (FPM method) was used for quantitative analysis.
Pharmacokinetic Analysis The plasma concentrationtime data for tetracycline and ciprofloxacin after a single oral administration were analyzed for each subject by the noncompartmental method. The observed maximum concentration (C max ) and the time to C max (T max ) were determined for each subject by inspection of the plasma concentration-time curves. The area under the concentration versus time curve (AUC ∞ ) and the area under the first-moment curve (AUMC) after oral administration were calculated by the linear trapezoidal rule and extrapolated to infinity by adding the ratio of the last measurable concentration to the terminal elimination rate constant (k el ), which was calculated by determining the slope of the least-squares regression line from the terminal portion of the log concentration-time data. The AUC from time zero to 24 h after the oral administration (AUC 0-24 ) was determined by the linear trapezoidal rule. The systemic clearance (CL SYS /F) was calculated as dose/AUC, in which F is bioavailability. The mean residence time (MRT) was calculated as MRTϭAUMC/AUC. The apparent steady-state volume of distribution (V SS /F) was calculated as V SS /Fϭ CL SYS /FϫMRT. The terminal elimination half-life (T 1/2 ) was calculated as 0.693 divided by k el . The renal clearance (CL R ) was determined by dividing the total amount of the unchanged drug excreted into the urine within the collection period (24 h) by the corresponding AUC (AUC 0-24 ).
Statistic Analysis All values are expressed as meansϮ standard deviations. Statistical comparisons between the groups were assessed by the paired t-test, with pϽ0.05 being the minimum level of significance.
RESULTS
In the present study, no major side effects were observed throughout this clinical trial. The amounts of the major cationic metals in the Kampo preparation measured by XRay fluorescence element analyzer are summarized in Table  1B . In various metals, calcium was the most commonly con- Figure 1 shows the mean semilogarithmic plasma concentration-time curves of ciprofloxacin for the ten subjects who received ciprofloxacin (200 mg) alone and with the coadministration of the Kampo preparation. Significant differences in the plasma concentrations of ciprofloxacin were observed between the values obtained when ciprofloxacin alone was administered (1.14Ϯ0.41 mg/ml) and those obtained when the Kampo preparation was coadministered (0.66Ϯ0.41 mg/ml) at 0.5 h after oral administration, although large interindividual variations of the concentrations in the absorption phase were observed. However, the Kampo preparation did not alter the disappearance of ciprofloxacin from plasma. The effect of the Kampo preparation on the pharmacokinetic parameters of ciprofloxacin is summarized in Table 2 . The Kampo preparation significantly, but slightly, decreased the area under the plasma concentration-time curves (AUC ∞ ) and peak plasma concentration (C max ) of ciprofloxacin by 15% and 20%, respectively. However, it had no effect on the time to C max (T max ). In order to clarify the effect of the Kampo preparation on the renal excretion of ciprofloxacin, we compared the concentrations of ciprofloxacin in the urine after administration of ciprofloxacin alone with those followed by coadministration with the Kampo preparation. As shown in Table 2 , no significant differences in the mean percentage of dose excreted as unchanged ciprofloxacin recovered in urine over 24 h (47.5Ϯ21.6 and 52.6Ϯ27.0%) and renal clearance (16.1Ϯ7.89 and 14.6Ϯ6.64 l/h) were observed between in the presence and absence of the Kampo preparation, although large variations were observed.
Mean semilogarithmic plots of plasma concentration-time data for a single oral administration of tetracycline (250 mg) with or without the Kampo preparation are illustrated in Fig.  2 . As shown in Fig. 2 , significant differences in the plasma concentrations of tetracycline between subjects treated with and without the Kampo preparation were observed at the all sampling times. The Kampo preparation, however, did not alter the disappearance of tetracycline from plasma. Table 3 shows the corresponding pharmacokinetic parameters of tetracycline. The Kampo preparation significantly decreased the values of AUC ∞ , C max and urinary recovery of tetracycline by 30% (27.9 to 19.7 mg · h/ml), 28% (2.26 to 1.63 mg/ml) and 32% (67.8 to 45.7%), respectively. However, it had no effect on the CL R and T max of tetracycline.
DISCUSSION
There are many published papers demonstrating that concomitant administration of antacids containing cationic metals such as calcium, aluminum and magnesium reduces the bioavailability of ciprofloxacin and tetracycline by forming insoluble chelates. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In the present study, it was confirmed that the amount of calcium contained in the Kampo preparation investigated in this study are much higher than that of 1082 Vol. 32, No. 6 Each value represents mg per one package (3 g) and the meanϮstandard deviation (nϭ3). Table 2 . Pharmacokinetic Parameters of Ciprofloxacin after a Single Oral Administration with and without Byakkokaninjinto (TJ-34) in Healthy Volunteers aluminum (0.6 mg) or magnesium (2.1 mg). These results suggest that the amount of other cationic metals except for calcium is negligible and that calcium might be the key factor of which the Kampo preparation changes the bioavailability of these two antimicrobial agents. It is believed that the possibility of interaction between these two antimicrobial agents and the Kampo preparation is low because the content of calcium contained in the Kampo preparation is remarkably lower than that in antacids used clinically.
The present study demonstrated that the Kampo preparation, byakkokaninjinto, decreases slightly the extent of bioavailability of ciprofloxacin and moderately that of tetracycline in healthy male volunteers and that the magnitude of the decreased bioavailability of tetracycline was much greater than that of ciprofloxacin (30% and 15%, respectively), suggesting that the affinity of tetracycline to calcium is higher than that of ciprofloxacin. Jung et al. 15) have reported that almost the same amount of calcium (37.5 mg) as the present study reduces the bioavailability of tetracycline (250 mg) by approximately 50%, which supports the results of the present study.
The estimated pharmacokinetic parameters of ciprofloxacin and tetracycline after a single oral administration in the absence of the Kampo preparation, such as C max , which was 1.35 mg/ml for ciprofloxacin and 2.26 mg/ml for tetracycline, and T max , which was 0.85 h for ciprofloxacin and 2.8 h for tetracycline, were almost identical to the published data. 17, 18) It was found that the rate of gastrointestinal absorption of ciprofloxacin is three times faster than that of tetracycline. The apparent T 1/2 values (approximately 8 h) for both antimicrobial agents were also nearly equal to the normal values.
In the present study, the Kampo preparation had no effect on the T max values of these two antimicrobial agents, suggesting that the Kampo preparation does not influence the gastric emptying time (GET) of them. On the other hand, the gastrointestinal absorption of tetracycline, but not ciprofloxacin, is reported to be influenced by gastrointestinal pH. 19, 20) Considering that the in vitro experiment showed no changes in the pH of the artificial gastrointestinal fluid (pH 6.8) in the presence of the Kampo preparation, it is unlikely that the decreased extent of bioavailability of tetracycline by the Kampo preparation may be due to the increase in the gastrointestinal pH. It was also suggested that calcium plays an important role in the chelation of each of the studied drugs with cationic metals. On the basis of these findings, we can conclude that the decreased extent of bioavailability of tetracycline by the Kampo preparation might be due to insoluble forms by chelation with calcium. It has been reported that an interval of 3 h between administration of tetracycline and cationic metals is needed to pre-avoid the pharmacokinetic interaction, 21) although the compliance may be decreased.
It has been reported that coadministration with a large dose of calcium (500 mg) as calcium carbonate tablet formulation reduces the bioavailability of ciprofloxacin by approximately 40%.
14) Neuvonen et al. 11) have also reported that concomitant administration of a large dose of calcium as milk product (360 mg) reduces the bioavailability of ciprofloxacin by 33%. In contrast, it is reported that pretreatment with a large dose of calcium (500 mg) as tablet formulation 2 h before the administration of ciprofloxacin did not alter the bioavailability of ciprofloxacin, thus it is recommended that ciprofloxacin is administered 2 h after taking calcium. 22, 23) It is likely that this phenomenon may be explained by the difference in the time interval between calcium administration and ciprofloxacin dosing, which avoids the formation of calcium-ciprofloxacin complexes, but not by the difference in liquid and tablet forms although the precise reason remains unclear. Considering that the amount of calcium contained in the Kampo preparation is extensively smaller compared with the dose of ciprofloxacin studied and that in their studies, the observed slight decrease in the bioavailability of ciprofloxacin by the Kampo preparation may be supported by the results of their studies. The binding of ciprofloxacin with calcium metals is much weaker than aluminum. 24) Also, the order of the stability constants for calcium-ciprofloxacin complex has been reported to be the lowest among various divalent cationic metals. 25) Based on these observations, it is relevant that only a slight decrease in the bioavailability of ciprofloxacin by the Kampo preparation was observed in this study. We can conclude that the Kampo preparation containing a small amount of calcium has negligible effects on the extent of bioavailability and antibacterial therapy of ciprofloxacin.
It has been reported that ciprofloxacin is metabolized in a small amount and partly excreted into bile and that the plasma protein binding potency is low. 26) In the present study, the mean percentage of ciprofloxacin excreted in the urine within 24 h was approximately 50%, which were identical to the data reported previously 11, 26) and insignificantly different from those of subjects treated with the Kampo preparation. There were also no significant differences in the terminal elimination rate constant (k el ) between in the presence and absence of the Kampo preparation (0.08 and 0.08 h
Ϫ1
, respectively). These results suggest that the Kampo preparation has no effect on the renal excretion of ciprofloxacin. The mean CL R values of ciprofloxacin in subjects untreated with the Kampo preparation were 243.0 ml/min, which were twotimes greater than the value of the normal glomerular filtration rate (GFR) of 120 ml/min, and the calculated clearance ratio (CL R /GFR) was approximately 2, suggesting that ciprofloxacin is actively secreted into the urine by the certain drug transporters localized in the renal tubules.
On the other hand, the percentages of tetracycline recov- Table 3 . Pharmacokinetic Parameters of Tetracycline after a Single Oral Administration with and without Byakkokaninjinto (TJ-34) in Healthy Volunteers ered in the urine within 24 h, but not CL R , were significantly decreased by the concomitant administration of the Kampo preparation (67.8 to 45.7%). The f e value of tetracycline in the presence of the Kampo preparation is calculated to be 67.6% of that in the absence of the Kampo preparation, whereas the CL SYS /F and V SS /F values of tetracycline in the presence of the Kampo preparation calculated to be 150% and 152% of those in the absence of the Kampo preparation, respectively. These results strongly suggest that the increased CL SYS /F and V SS /F values of tetracycline in the presence of the Kampo preparation were caused by the decreased bioavailability (F). The mean CL R values of tetracycline were 116.2 ml/min. The plasma protein binding potency of tetracycline is 60% 18) and the CL R for tetracycline unbound to plasma proteins (CL RU ) was recalculated by CL RU ϭCL R /unbound fraction (f U ). The resulting values of 290.5 ml/min indicate the existence of the tubular secretion, which were supported by the report by Babu and colleagues. 27) There is an interesting report indicating that one of the constituents of the Kampo preparation, Glycyrrhizae radix, has an inhibitory effect on the efflux pump mediated by P-glycoprotein. 28) It is reported that ATP binding cassette (ABC) efflux transporters such as multidrug resistance associated protein 2 (ABCC2/MRP2) and ABCB1/P-glycoprotein are involved in the absorption and excretion of some quinolone antimicrobial agents. 17, 29, 30) Among the quinolone antimicrobial agents, ciprofloxacin is excreted into bile and urine by the drug efflux transporter, breast cancer resistance protein (BCRP/ABCG2), but not P-glycoprotein. 31) In contrast, the human organic anion transporters hOAT1, hOAT2 and hOAT3 are involved in the basolateral uptake and/or efflux of tetracycline, whereas hOAT4 is involved in the reabsorption of tetracycline in the proximal tubule. 27) On the basis of these findings, it is likely that the Kampo preparation has no effect on such drug efflux transporters-mediated excretion of ciprofloxacin and tetracycline.
In conclusion, the present study demonstrated that the Kampo preparation, byakkokaninjinto, moderately decreases the bioavailability of tetracycline even though the amount of calcium is very low, suggesting importance of the time interval between the Kampo preparation and tetracycline dosings. In contrast, changes in the bioavailability of ciprofloxacin by the Kampo preparation were slight, suggesting that the effect of the Kampo preparation on antibacterial therapy with ciprofloxacin is negligible.
